Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.

European journal of clinical investigation - 1 Jun 2018

Serna María José, Rivera-Caravaca José Miguel, Gonzalez-Conejero Rocío, Esteve-Pastor María Asunción, Valdés Mariano, Vicente Vicente, Lip Gregory Y H, Roldán Vanessa, Marín Francisco

Abstract excerpt

BACKGROUND: Polymorphisms in the vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes increase the bleeding risk in anticoagulated atrial fibrillation (AF) patients. Here, we aimed to investigate whether VKORC1 and CYP2C9 polymorphisms improved the predictive performance for major bleeding using the HAS-BLED score. MATERIAL AND METHODS: We recruited 652 consecutive AF patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atrial Fibrillation

Share to Cytochrome P-450 CYP2C9

Share to Gastrointestinal Hemorrhage

Share to Hemorrhage

Share to Intracranial Hemorrhages

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 29577257
DOI: 10.1111/eci.12929

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.PMID 29577257Read ↗

Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.Semantic proximity Read ↗

The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.Semantic proximity Read ↗

Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case-cohort.Semantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Integrating genotypes in the SAMe-TT2R2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin.Semantic proximity Read ↗

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Semantic proximity Read ↗

VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.Semantic proximity Read ↗

Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.Semantic proximity Read ↗

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort studySemantic proximity Read ↗

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case SeriesSemantic proximity Read ↗

Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients.Semantic proximity Read ↗

Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.